Generic API List

CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities. 

Highlights CordenPharma's capabilities for Oral Solid Dosage and Non-Sterile Dosage forms as well as Sterile Injectable Drug Product manufacturing.

The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. 

The Peptides, Lipids & Carbohydrates Platform provides you with advanced Bio-Organic APIs, including synthetic Peptides, Lipids, Carbohydrates & Conjugates, from early-stage to commercial.

In this interview from CPHI Frankfurt 2022, we speak to Dr Michael Quirmbach of CordenPharma about his role as President and CEO and what CordenPharma is bringing to the pharma industry.

The Highly Potent & Oncology Platform supports your project from clinical through commercial with the development & production of highly potent APIs, Oral Solid Dosage Forms & Injectable Drug Products including ready-for-market packaging, labeling & serialization.

Luxembourg, 19 April 2021 -- In response to the COVID-19 pandemic, mRNA (messenger RNA) vaccines have catapulted to center stage of the pharmaceutical and biotechnology industry. As of early 2021, there are eight ongoing human trials for mRNA vaccines led by Moderna, BioNTech / Pfizer, CureVac, Sanofi / TranslateBio, Arcturus / Duke-NUS Medical School (Singapore), Imperial College London, Chulalongkorn University (Thailand), and Providence Therapeutics.

Our Injectables Platform offers you a broad spectrum of injectable services starting from early-formulation development to full commercial scale, covering both terminal sterilization & aseptic filling. Packaging, labeling & clinical trial kit management round off this service.

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

Under the Small Molecules Platform we develop and advance your project through all phases to commercial, from advanced intermediates to drug products, from kilogram to multi-ton production volumes annually.

11 April 2022 - Munich / Halle / Plankstadt

• WACKER AND CORDENPHARMA TO BECOME PART OF GERMANY’S PANDEMIC PREPAREDNESS PLANTHE TWO COMPANIES WILL BE READY TO PRODUCE MRNA VACCINES FOR THE GERMAN GOVERNMENT IF THE COVID-19 PANDEMIC CONTINUES OR A NEW PANDEMIC OCCURS
• WACKER AND CORDENPHARMA JOINTLY COVER THE ENTIRE MANUFACTURING CHAIN FOR VACCINES
• HALLE WILL BECOME A COMPETENCE CENTER FOR PRODUCING MRNA VACCINES, WITH ADDITIONAL CAPACITY FOR OTHER CUSTOMERS AS WELL
• CORDENPHARMA WILL USE ITS YEARS OF EXPERIENCE IN PRODUCING CUSTOM AND STANDARD LIPIDS AND IN FILL & FINISH
• WACKER INTENDS TO INVEST OVER €80 MILLION ANNUALLY IN EXPANDING THE GROWTH OF ITS BIOTECHNOLOGY BUSINESS OVER THE NEXT FEW YEARS

CordenPharma is your Full-Service CDMO partner for the manufacturing of APIs, Drug Products & Packaging. Through an integrated network of cGMP facilities organized under four Technology Platforms - Peptides, Oligonucleotides, Lipids, & Carbohydrates - Highly Potent & Oncology – Injectables - Small Molecules - CordenPharma experts translate complex processes at any stage of development into high-value products. 

Luxembourg, 28 May 2020 -- CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) for the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the signing of an amendment to their existing manufacturing agreement with Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients.

CordenPharma offers a wide selection of Readily Available Derivatized Phospholipids suitable for Research & Discovery for purchase in convenient 1 g and 10 g pack sizes.

WeylChem InnoTec are your innovative partner to the fine chemical, pharmaceutical and electronic industry. We provide world-class analytical, modern developmental and tailor-made manufacturing services. With our competencies in Analytics, Contract Development & Custom Synthesis, WeylChem InnoTec is your agile development partner.

Our Services:AnalyticsContract DevelopmentCustom SynthesisAdvanced technologies
How We Support You in Different Markets:
Organic ElectronicsCatalysts and LigandsSustainable ChemistryPharmaceutical IntermediatesAgrochemicalsVisit weylchem-innotec.com or email [email protected] for more information.

CordenPharma’s early-phase Drug Product services & bioavailability enhancement address formulations containing solubility- or permeability-challenged APIs.

Let us accompany you on your Sterile Injectable Drug Product journey under CordenPharma's Injectable Technology Platform. Our CordenPharma Caponango (IT) manufacturing facility produces liquid dosage forms with expertise in GMP Manufacturing, Aspetic Fill & Finish, Terminal Sterilization, Clinical Trials, and Pharma-Logistics.

CordenPharma is your partner of choice in the development and manufacturing of Highly Potent APIs. Our facilities in Boulder, CO (USA) offer API synthesis from early clinical to commercial supply.

Download this CordenPharma White Paper Below > Get informed about packaging serialization regulatory requirements & deadlines for global markets in this CordenPharma white paper discussing keys to combating the worldwide drug counterfeiting problem. Topics include serialization techniques in the supply chain such as Microscopic RFID Tags, Security Labels, Invisible Inks, and Track-and-Trace Technologies, and a GS1 standard language called Electronic Product Code Information Services (EPCIS). Learn the importance and benefits of choosing the right CMO or CDMO to ensure the utmost level of support in keeping patients safe.

Register for this Live (4-4-18) or on Demand webinar to learn how the most important (and often over-looked) aspect to a robust containment program is the strength of the intangible, softer elements. Discuss how to maximize the success of your engineering control investments and allow for continued alignment to your company’s commitment to providing a workplace free of recognized health & safety hazards.

This recorded webinar archive addresses the necessity of serialization from market compliance to business supply. Expert speaker Mario Scigliano covers all aspects of serialization, from line choice and regulation approach to management of data and related products.

AuthorsDr. Oliver Schinzinger, Head of Pharmaceutical Development, CordenPharma Plankstadt
Dr. Eva Fahrländer, Scientific Lead, Formulation Development, CordenPharma Plankstadt
Dr. Christoph Rott, Head of Formulation Development, CordenPharma Plankstadt

Get informed about Pediatric Dosage Form Considerations for Highly Potent Compounds in this CordenPharma whitepaper discussing the benefits of Mini-Tablets as an effective pediatric dosage form. Topics include: Age Appropriate Dosage FormsFlexible & Accurate DosingExcipients & Taste MaskingManufacture & In-Process Control TestingChallenges Transitioning from Tablets to Mini-Tablets 

Our Fill & Finish Injectable Drug Product facility CordenPharma Caponago, near Milan, Italy, supports local hospitals with Propofol, an effective medicine that helps support COVID-19 patients.

CordenPharma Colorado works hard for continued business continuity and uses 3D Printer to produce Personal Protective Equipment for local healthcare workers during COVID-19.

Speaker: Dr. Robert Topping, Distinguished Scientist, CordenPharma Colorado

Key Learning Objectives
Learn how large is large-scale peptide manufacturing.What are the factors that change on large-scale manufacturing which could impact product quality & process operations?What are the areas of risk encountered when scaling up?Review safety, health & environmental considerations.

Your Injectable Roadmap for Combined Drug Product - Delivery Device Regulations & Evolving Capabilities in the New Normal > How a Full-Service CDMO Supports Pharma

Speakers: Mark Chipperfield (Corvus Ltd), Fabio Stevanon (CordenPharma), Umberto Romeo (CordenPharma)
Key Learning Objectives:
Review the fundamentals of combined injectable delivery device - drug products. Get an update on the latest regulation landscape for combined drug-device products, including some technical challenges for injectable Pre-Filled Syringes (PFS) & Auto-injectors. Gain insight into sound Injectable Drug Product strategy from a Full-Service CDMO industry leader. Learn about recent injectable industry changes facing Pharma, especially in the “New Normal” COVID-19 era, and how CordenPharma’s successful response & expanded capabilities can best support your drug development goals. Learn from an R&D Expert on ways to efficiently develop & commercialize an injectable drug.